Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-04-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于获得药品临床试验申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (861 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug by the National Medical Products Administration. It contains no financial data, no detailed financial statements, nor any management discussion of financial results. It is an official announcement about regulatory approval status related to drug development. The document is not a report, transcript, or detailed financial filing. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2020-04-12 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2020 年第一季度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2020 First Quarter Report Full Text." It contains detailed financial data including income, net profit, cash flow, assets, liabilities, shareholders' information, and financial statements as of March 31, 2020. The document includes comprehensive financial tables and management commentary on financial performance for the first quarter of 2020. The presence of quarterly financial statements and detailed financial analysis indicates this is a quarterly financial report rather than an earnings release or an announcement. The length of the document (15,000 characters) and the detailed financial content confirm it is a full interim/quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2020
2020-04-10 Chinese
2019年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2019年度监事会工作报告" which translates to "2019 Supervisory Board Work Report". It details the supervisory board's activities, meetings, and oversight of the company's operations, financials, internal controls, and compliance during the 2019 fiscal year. It references the review and supervision of quarterly reports, half-year reports, and the annual report, but it is itself a report on the supervisory board's work and oversight, not the full annual report or financial statements. The document contains substantive content about the supervisory board's work and oversight, not just an announcement or certification. This type of document aligns best with an Audit Report / Information (AR) category, as it focuses on supervisory and audit-related oversight rather than the full annual report (10-K) or other categories. The document length is 3746 characters, which is substantive but not extremely long, consistent with a supervisory board report. Therefore, the best classification is AR with high confidence. FY 2019
2020-04-10 Chinese
2019年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2019 年度内部控制自我评价报告' which translates to '2019 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control evaluation for the fiscal year ending December 31, 2019, including the scope, standards, and conclusions about internal control effectiveness. The content focuses on internal control assessment rather than full financial statements or comprehensive annual performance. It is not an Annual Report (10-K) or an Interim Report (IR) because it lacks full financial data and broader company performance details. It is not an Audit Report (AR) since it is a self-evaluation report by the company, not an external auditor's report. The document is substantive and detailed, not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). The document fits best under Audit Report / Information (AR) as it relates to internal control evaluation and compliance with internal control standards, which is typical for standalone audit-related reports. FY 2019
2020-04-10 Chinese
关于受让信立泰（苏州）药业有限公司少数股东股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of minority shareholder equity in a subsidiary company by Shenzhen Xintai Pharmaceutical Co., Ltd. It details the transaction overview, parties involved, financial data of the target company, transaction terms, and the impact and risks associated with the transaction. The document includes board approval information and financial figures but does not contain comprehensive financial statements or detailed financial performance analysis typical of annual or interim reports. It is a corporate announcement about a capital transaction (equity acquisition) and financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6843 characters) and content confirm it is a full announcement rather than a brief notice or a report publication announcement.
2020-04-10 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding a change in accounting policies. It details the reasons for the change, the new accounting standards adopted, the decision-making process by the board and supervisory committee, and the opinions of independent directors and the supervisory board. The document does not contain financial statements or detailed financial data but rather informs shareholders and the public about the accounting policy change and its expected impact. The document length is 2542 characters, which is relatively short and consistent with an announcement rather than a full report. It is not a full Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is not a regulatory certification or officer attestation. The content fits best with a Regulatory Filing (RNS) as it is a formal disclosure of a significant accounting policy change without detailed financial data or analysis.
2020-04-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.